Cell-based therapies for Parkinson disease-past insights and future potential

Nature Reviews Neurology

Volumn 11, Issue 9, 2015, Pages 492-503

  Barker, Roger A ^a   Drouin Ouellet, Janelle ^b   Parmar, Malin ^b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

6 FLUORODOPA F 18; AZATHIOPRINE; CARBIDOPA PLUS LEVODOPA; CYCLOSPORIN A; STEROID;

ADRENAL MEDULLA; BRAIN DEPTH STIMULATION; DOPAMINERGIC NERVE CELL; EMBRYONIC STEM CELL; ENGRAFTMENT; GOOD MANUFACTURING PRACTICE; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; MESENCEPHALON; NERVE CELL DIFFERENTIATION; NERVE TRANSPLANTATION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PATIENT SELECTION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PLURIPOTENT STEM CELL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STEM CELL TRANSPLANTATION; TISSUE PREPARATION; UNIFIED PARKINSON DISEASE RATING SCALE; ANIMAL; BIOLOGICAL THERAPY; CLINICAL TRIAL (TOPIC); PATHOPHYSIOLOGY; PROCEDURES;

ANIMALS; CELL- AND TISSUE-BASED THERAPY; CLINICAL TRIALS AS TOPIC; HUMANS; PARKINSON DISEASE;

EID: 84941022742     PISSN: 17594758     EISSN: 17594766     Source Type: Journal    
DOI: 10.1038/nrneurol.2015.123     Document Type: Review

References (145)

1. Spillantini, M. G. et al. a Synuclein in Lewy bodies. Nature 388, 839-840 (1997
2. Damier, P., Hirsch, E. C., Agid, Y. & Graybiel, A. M. The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinsons disease. Brain 122, 1437-1448 (1999
3. Braak, H. et al. Staging of brain pathology related to sporadic Parkinsons disease. Neurobiol. Aging 24, 197-211 (2003
4. Jenner, P. Dopamine agonists, receptor selectivity and dyskinesia induction in Parkinsons disease. Curr. Opin. Neurol. 16 (Suppl. 1), S3-S7 (2003
5. Huot, P., Johnston, T. H., Koprich, J. B., Fox, S. H. & Brotchie, J. M. The pharmacology of l DOPA induced dyskinesia in Parkinsons disease. Pharmacol. Rev. 65, 171-222 (2013
6. Thompson, W. G. Successful brain grafting. N. Y. Med. J. 51, 701-702 (1890
7. Olson, L. & Seiger, A. Brain tissue transplanted to the anterior chamber of the eye: 2. Fluorescence histochemistry of immature catecholamine-And 5 hydroxytryptamine neurons innervating the rat vas deferens. Cell Tissue Res. 158, 141-150 (1975
8. Olson, L. & Seiger, A. Development and growth of immature monoamine neurons in rat and man in situ and following intraocular transplantation in the rat. Brain Res. 62, 353-360 (1973
9. Olson, L. & Seiger, A. Brain tissue transplanted to the anterior chamber of the eye. 1. Fluorescence histochemistry of immature catecholamine and 5 hydroxytryptamine neurons reinnervating the rat iris. Z. Zellforsch. Mikrosk. Anat. 135, 175-194 (1972
10. Barker, R. & Dunnett, S. The biology and behaviour of intracerebral adrenal transplants in animals and man. Rev. Neurosci. 4, 113-146 (1993
11. Ungerstedt, U., Ljungberg, T. & Steg, G. Behavioral, physiological, and neurochemical changes after 6 hydroxydopamine induced degeneration of the nigro-striatal dopamine neurons. Adv. Neurol. 5, 421-426 (1974
12. Ungerstedt, U. & Arbuthnott, G. W. Quantitative recording of rotational behavior in rats after 6 hydroxy dopamine lesions of the nigrostriatal dopamine system. Brain Res. 24, 485-493 (1970
13. Ungerstedt, U. 6 Hydroxy dopamine induced degeneration of central monoamine neurons. Eur. J. Pharmacol. 5, 107-110 (1968
14. Hudson, J. L. et al. Correlation of apomorphine-And amphetamine-induced turning with nigrostriatal dopamine content in unilateral 6 hydroxydopamine lesioned rats. Brain Res. 626, 167-174 (1993
15. Freed, W. J. et al. Transplanted adrenal chromaffin cells in rat brain reduce lesion-induced rotational behaviour. Nature 292, 351-352 (1981
16. Perlow, M. J. et al. Brain grafts reduce motor abnormalities produced by destruction of nigrostriatal dopamine system. Science 204, 643-647 (1979
17. Hoffer, B., Freed, W., Olson, L. & Wyatt, R. J. Transplantation of dopamine-containing tissues to the central nervous system. Clin. Neurosurg. 31, 404-416 (1983
18. Freed, W. J. et al. Restoration of dopaminergic function by grafting of fetal rat substantia nigra to the caudate nucleus: long-term behavioral, biochemical, and histochemical studies. Ann. Neurol. 8, 510-519 (1980
19. Björklund, A., Stenevi, U., Dunnett, S. B. & Iversen, S. D. Functional reactivation of the deafferented neostriatum by nigral transplants. Nature 289, 497-499 (1981
20. Björklund, A., Dunnett, S. B., Stenevi, U., Lewis, M. E. & Iversen, S. D. Reinnervation of the denervated striatum by substantia nigra transplants: functional consequences as revealed by pharmacological and sensorimotor testing. Brain Res. 199, 307-333 (1980
21. Björklund, A. & Stenevi, U. Reconstruction of the nigrostriatal dopamine pathway by intracerebral nigral transplants. Brain Res. 177, 555-560 (1979
22. Björklund, A., Stenevi, U., Schmidt, R. H., Dunnett, S. B. & Gage, F. H. Intracerebral grafting of neuronal cell suspensions. II. Survival and growth of nigral cell suspensions implanted in different brain sites. Acta Physiol. Scand. Suppl. 522, 9-18 (1983
23. Brundin, P., Barker, R. A. & Parmar, M. Neural grafting in Parkinsons disease: problems and possibilities. Prog. Brain Res. 184, 265-294 (2010
24. Barker, R. A. What have open label studies of cell based therapies for Parkinsons disease told us, if anything?. Basal Ganglia 4, 85-87 (2014
25. Backlund, E. O. et al. Transplantation of adrenal medullary tissue to striatum in parkinsonism. First clinical trials. J. Neurosurg. 62, 169-173 (1985
26. Freed, W. J., Poltorak, M. & Becker, J. B. Intracerebral adrenal medulla grafts: A review. Exp. Neurol. 110, 139-166 (1990
27. Madrazo, I. et al. Open microsurgical autograft of adrenal medulla to the right caudate nucleus in two patients with intractable Parkinsons disease. N. Engl. J. Med. 316, 831-834 (1987
28. Moore, R. Y. Parkinsons disease-A new therapy?. N. Engl. J. Med. 316, 872-873 (1987
29. Allen, G. S., Burns, R. S., Tulipan, N. B. & Parker, R. A. Adrenal medullary transplantation to the caudate nucleus in Parkinsons disease. Initial clinical results in 18 patients. Arch. Neurol. 46, 487-491 (1989
30. Drucker-Colin, R. et al. Adrenal medullary tissue transplants in the caudate nucleus of Parkinsons patients. Prog. Brain Res. 78, 567-574 (1988
31. Goetz, C. G. et al. Multicenter study of autologous adrenal medullary transplantation to the corpus striatum in patients with advanced Parkinsons disease. N. Engl. J. Med. 320, 337-341 (1989
32. Goetz, C. G. et al. Adrenal medullary transplant to the striatum of patients with advanced Parkinson disease: 1 year motor and psychomotor data. Neurology 40, 273-276 (1990
33. Jankovic, J. et al. Clinical, biochemical, and neuropathologic findings following transplantation of adrenal medulla to the caudate nucleus for treatment of Parkinsons disease. Neurology 39, 1227-1234 (1989
34. Jiao, S. S. et al. Study of adrenal medullary tissue transplantation to striatum in parkinsonism. Prog. Brain Res. 78, 575-580 (1988
35. Jiao, S. S. et al. Adrenal medullary autografts in patients with Parkinsons disease. N. Engl. J. Med. 321, 324-327 (1989
36. Kelly, P. J. et al. Adrenal medullary autograft transplantation into the striatum of patients with Parkinsons disease. Mayo Clin. Proc. 64, 282-290 (1989
37. Lindvall, O. et al. Transplantation in Parkinsons disease: two cases of adrenal medullary grafts to the putamen. Ann. Neurol. 22, 457-468 (1987
38. Ostrosky-Solis, F. et al. Neuropsychological effects of brain autograft of adrenal medullary tissue for the treatment of Parkinsons disease. Neurology 38, 1442-1450 (1988
39. Goetz, C. G. et al. United Parkinson Foundation Neurotransplantation Registry on adrenal medullary transplants: presurgical, and 1 and 2 year follow-up. Neurology 41, 1719-1722 (1991
40. Hurtig, H., Joyce, J., Sladek, J. R. J. & Trojanowski, J. Q. Postmortem analysis of adrenal medulla to-caudate autograft in a patient with Parkinsons disease. Ann. Neurol. 25, 607-614 (1989
41. Kompoliti, K., Chu, Y., Shannon, K. M. & Kordower, J. H. Neuropathological study 16 years after autologous adrenal medullary transplantation in a Parkinsons disease patient. Mov. Disord. 22, 1630-1633 (2007
42. Kordower, J. H., Cochran, E., Penn, R. D. & Goetz, C. G. Putative chromaffin cell survival and enhanced host-derived TH fiber innervation following a functional adrenal medulla autograft for Parkinsons disease. Ann. Neurol. 29, 405-412 (1991
43. Waters, C., Itabashi, H. H., Apuzzo, M. L. & Weiner, L. P. Adrenal to caudate transplantation-postmortem study. Mov. Disord. 5, 248-250 (1990
44. Lindvall, O. et al. Human fetal dopamine neurons grafted into the striatum in two patients with severe Parkinsons disease. A detailed account of methodology and a 6 month follow-up. Arch. Neurol. 46, 615-631 (1989
45. Lindvall, O. et al. Grafts of fetal dopamine neurons survive and improve motor function in Parkinsons disease. Science 247, 574-577 (1990
46. Brundin, P. et al. Bilateral caudate and putamen grafts of embryonic mesencephalic tissue treated with lazaroids in Parkinsons disease. Brain 123, 1380-1390 (2000
47. Lindvall, O. et al. Evidence for long-term survival and function of dopaminergic grafts in progressive Parkinsons disease. Ann. Neurol. 35, 172-180 (1994
48. Wenning, G. K. et al. Short-And long-term survival and function of unilateral intrastriatal dopaminergic grafts in Parkinsons disease. Ann. Neurol. 42, 95-107 (1997
49. Piccini, P. et al. Dopamine release from nigral transplants visualized in vivo in a Parkinsons patient. Nat. Neurosci. 2, 1137-1140 (1999
50. Piccini, P. et al. Delayed recovery of movement-related cortical function in Parkinsons disease after striatal dopaminergic grafts. Ann. Neurol. 48, 689-695 (2000
51. Kefalopoulou, Z. et al. Long-term clinical outcome of fetal cell transplantation for Parkinson disease: two case reports. JAMA Neurol. 71, 83-87 (2014
52. Freed, C. R. et al. Survival of implanted fetal dopamine cells and neurologic improvement 12 to 46 months after transplantation for Parkinsons disease. N. Engl. J. Med. 327, 1549-1555 (1992
53. Freeman, T. B. et al. Bilateral fetal nigral transplantation into the postcommissural putamen in Parkinsons disease. Ann. Neurol. 38, 379-388 (1995
54. Redmond, D. E. et al. Cellular replacement of dopamine deficit in Parkinsons disease using human fetal mesencephalic tissue: preliminary results in four patients. Res. Publ. Assoc. Res. Nerv. Ment. Dis. 71, 325-359 (1993
55. Widner, H. et al. Bilateral fetal mesencephalic grafting in two patients with parkinsonism induced by 1 methyl 4 phenyl 1,2,3,6-tetrahydropyridine (MPTP). N. Engl. J. Med. 327, 1556-1563 (1992
56. Mendez, I. et al. Enhancement of survival of stored dopaminergic cells and promotion of graft survival by exposure of human fetal nigral tissue to glial cell line-derived neurotrophic factor in patients with Parkinsons disease. Report of two cases and technical considerations. J. Neurosurg. 92, 863-869 (2000
57. Mendez, I. et al. Simultaneous intrastriatal and intranigral fetal dopaminergic grafts in patients with Parkinson disease: A pilot study. Report of three cases. J. Neurosurg. 96, 589-596 (2002
58. Widner, H. NIH neural transplantation funding. Science 263, 737 (1994
59. Kumar, R. et al. Double-blind evaluation of subthalamic nucleus deep brain stimulation in advanced Parkinsons disease. Neurology 51, 850-855 (1998
60. Freed, C. R. et al. Transplantation of embryonic dopamine neurons for severe Parkinsons disease. N. Engl. J. Med. 344, 710-719 (2001
61. Olanow, C. W. et al. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinsons disease. Ann. Neurol. 54, 403-414 (2003
62. Cho, C., Alterman, R., Miravite, J., Shils, J. & Tagliati, M. Subthalamic DBS for the treatment of runaway dyskinesias after embryonic or fetal tissue transplant. Mov. Disord. 20, 1237 (2005
63. Graff-Radford, J. et al. Deep brain stimulation of the internal segment of the globus pallidus in delayed runaway dyskinesia. Arch. Neurol. 63, 1181-1184 (2006
64. Herzog, J. et al. Deep brain stimulation in Parkinsons disease following fetal nigral transplantation. Mov. Disord. 23, 1293-1296 (2008
65. Hagell, P. et al. Dyskinesias following neural transplantation in Parkinsons disease. Nat. Neurosci. 5, 627-628 (2002
66. Ma, Y. et al. Dyskinesia after fetal cell transplantation for parkinsonism: A PET study. Ann. Neurol. 52, 628-634 (2002
67. Barker, R A. & Kuan, W. L. Graft-induced dyskinesias in Parkinsons disease: what is it all about?. Cell Stem Cell 7, 148-149 (2010
68. Politis, M. et al. Serotonergic neurons mediate dyskinesia side effects in Parkinsons patients with neural transplants. Sci. Transl. Med. 2, 38ra46 (2010
69. Politis, M. et al. Graft-induced dyskinesias in Parkinsons disease: high striatal serotonin/dopamine transporter ratio. Mov. Disord. 26, 1997-2003 (2011
70. Lane, E. L., Winkler, C., Brundin, P. & Cenci, M. A. The impact of graft size on the development of dyskinesia following intrastriatal grafting of embryonic dopamine neurons in the rat. Neurobiol. Dis. 22, 334-345 (2006
71. Winkler, C., Georgievska, B., Carlsson, T., Lacar, B. & Kirik, D. Continuous exposure to glial cell line-derived neurotrophic factor to mature dopaminergic transplants impairs the graft ability to improve spontaneous motor behavior in parkinsonian rats. Neuroscience 141, 521-531 (2006
72. Mendez, I. et al. Cell type analysis of functional fetal dopamine cell suspension transplants in the striatum and substantia nigra of patients with Parkinsons disease. Brain 128, 1498-1510 (2005
73. Krack, P., Poepping, M., Weinert, D., Schrader, B. & Deuschl, G. Thalamic, pallidal, or subthalamic surgery for Parkinsons disease?. J. Neurol. 247 (Suppl. 2), II122-II134 (2000
74. Ma, Y. et al. Dopamine cell implantation in Parkinsons disease: long-term clinical and 18F-FDOPA PET outcomes. J. Nucl. Med. 51, 7-15 (2010
75. Barker, R. A., Barrett, J., Mason, S. L. & Björklund, A. Fetal dopaminergic transplantation trials and the future of neural grafting in Parkinsons disease. Lancet Neurol. 12, 84-91 (2013
76. Piccini, P. et al. Factors affecting the clinical outcome after neural transplantation in Parkinsons disease. Brain 128, 2977-2986 (2005
77. Kordower, J. H. et al. Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinsons disease. N. Engl. J. Med. 332, 1118-1124 (1995
78. Kordower, J. H. et al. Functional fetal nigral grafts in a patient with Parkinsons disease: chemoanatomic, ultrastructural, and metabolic studies. J. Comp. Neurol. 370, 203-230 (1996
79. Kordower, J. H. et al. Fetal nigral grafts survive and mediate clinical benefit in a patient with Parkinsons disease. Mov. Disord. 13, 383-393 (1998
80. TRANSEURO [online], http://www.transeuro.org.uk/ (2014
81. Barker, R. A., Kendall, A. L. & Widner, H. Neural tissue xenotransplantation: what is needed prior to clinical trials in Parkinsons disease?. Neural Tissue Xenografting Project. Cell Transplant. 9, 235-246 (2000
82. Galpern, W. R., Burns, L. H., Deacon, T. W., Dinsmore, J. & Isacson, O. Xenotransplantation of porcine fetal ventral mesencephalon in a rat model of Parkinsons disease: functional recovery and graft morphology. Exp. Neurol. 140, 1-13 (1996
83. Schumacher, J. M. et al. Transplantation of embryonic porcine mesencephalic tissue in patients with PD. Neurology 54, 1042-1050 (2000
84. Arjona, V. et al. Autotransplantation of human carotid body cell aggregates for treatment of Parkinsons disease. Neurosurgery 53, 321-328 (2003
85. Minguez-Castellanos, A. et al. Carotid body autotransplantation in Parkinson disease: A clinical and positron emission tomography study. J. Neurol. Neurosurg. Psychiatry 78, 825-831 (2007
86. Bakay, R. A. et al. Implantation of Spheramine in advanced Parkinsons disease (PD). Front. Biosci. 9, 592-602 (2004
87. Stover, N. P. et al. Intrastriatal implantation of human retinal pigment epithelial cells attached to microcarriers in advanced Parkinson disease. Arch. Neurol. 62, 1833-1837 (2005
88. Stover, N. P. & Watts, R. L. Spheramine for treatment of Parkinsons disease. Neurotherapeutics 5, 252-259 (2008
89. Watts, R. L. et al. Stereotaxic intrastriatal implantation of human retinal pigment epithelial (hRPE) cells attached to gelatin microcarriers: A potential new cell therapy for Parkinsons disease. J. Neural Transm. Suppl. 65, 215-227 (2003
90. Gross, R. E. et al. Intrastriatal transplantation of microcarrier-bound human retinal pigment epithelial cells versus sham surgery in patients with advanced Parkinsons disease: A double-blind, randomised, controlled trial. Lancet Neurol. 10, 509-519 (2011
91. Ribeiro, D. et al. Efficient expansion and dopaminergic differentiation of human fetal ventral midbrain neural stem cells by midbrain morphogens. Neurobiol. Dis. 49, 118-127 (2013
92. Barker, R. A. & De Beaufort, I. Scientific and ethical issues related to stem cell research and interventions in neurodegenerative disorders of the brain. Prog. Neurobiol. 110, 63-73 (2013
93. Barker, R. A. Developing stem cell therapies for Parkinsons disease: waiting until the time is right. Cell Stem Cell 15, 539-542 (2014
94. Thomson, J. A. et al. Embryonic stem cell lines derived from human blastocysts. Science 282, 1145-1147 (1998
95. Reubinoff, B. E., Pera, M. F., Fong, C. Y., Trounson, A. & Bongso, A. Embryonic stem cell lines from human blastocysts: somatic differentiation in vitro. Nat. Biotechnol. 18, 399-404 (2000
96. Itskovitz-Eldor, J. et al. Differentiation of human embryonic stem cells into embryoid bodies compromising the three embryonic germ layers. Mol. Med. 6, 88-95 (2000
97. Reubinoff, B. E. et al. Neural progenitors from human embryonic stem cells. Nat. Biotechnol. 19, 1134-1140 (2001
98. Zhang, S. C., Wernig, M., Duncan, I. D., Brustle, O. & Thomson, J. A. In vitro differentiation of transplantable neural precursors from human embryonic stem cells. Nat. Biotechnol. 19, 1129-1133 (2001
99. Kawasaki, H. et al. Induction of midbrain dopaminergic neurons from ES cells by stromal cell-derived inducing activity. Neuron 28, 31-40 (2000
100. Kim, J. H. et al. Dopamine neurons derived from embryonic stem cells function in an animal model of Parkinsons disease. Nature 418, 50-56 (2002
101. Brederlau, A. et al. Transplantation of human embryonic stem cell-derived cells to a rat model of Parkinsons disease: effect of in vitro differentiation on graft survival and teratoma formation. Stem Cells 24, 1433-1440 (2006
102. Park, C. H. et al. In vitro and in vivo analyses of human embryonic stem cell-derived dopamine neurons. J. Neurochem. 92, 1265-1276 (2005
103. Perrier, A. L. et al. Derivation of midbrain dopamine neurons from human embryonic stem cells. Proc. Natl Acad. Sci. USA 101, 12543-12548 (2004
104. Sonntag, K. C. et al. Enhanced yield of neuroepithelial precursors and midbrain-like dopaminergic neurons from human embryonic stem cells using the bone morphogenic protein antagonist noggin. Stem Cells 25, 411-418 (2007
105. Zeng, X. et al. Dopaminergic differentiation of human embryonic stem cells. Stem Cells 22, 925-940 (2004
106. Roy, N. S. et al. Functional engraftment of human ES cell-derived dopaminergic neurons enriched by coculture with telomerase-immortalized midbrain astrocytes. Nat. Med. 12, 1259-1268 (2006
107. Cooper, O. et al. Differentiation of human ES and Parkinsons disease iPS cells into ventral midbrain dopaminergic neurons requires a high activity form of SHH, FGF8a and specific regionalization by retinoic acid. Mol. Cell. Neurosci. 45, 258-266 (2010
108. Yan, Y. et al. Directed differentiation of dopaminergic neuronal subtypes from human embryonic stem cells. Stem Cells 23, 781-790 (2005
109. Yang, D., Zhang, Z. J., Oldenburg, M., Ayala, M. & Zhang, S. C. Human embryonic stem cell-derived dopaminergic neurons reverse functional deficit in parkinsonian rats. Stem Cells 26, 55-63 (2008
110. Takahashi, K., Okita, K., Nakagawa, M. & Yamanaka, S. Induction of pluripotent stem cells from fibroblast cultures. Nat. Protoc. 2, 3081-3089 (2007
111. Soldner, F. et al. Parkinsons disease patient-derived induced pluripotent stem cells free of viral reprogramming factors. Cell 136, 964-977 (2009
112. Hargus, G. et al. Differentiated Parkinson patient-derived induced pluripotent stem cells grow in the adult rodent brain and reduce motor asymmetry in parkinsonian rats. Proc. Natl Acad. Sci. USA 107, 15921-15926 (2010
113. Kikuchi, T. et al. Survival of human induced pluripotent stem cell-derived midbrain dopaminergic neurons in the brain of a primate model of Parkinsons disease. J. Parkinsons Dis. 1, 395-412 (2011
114. Bonilla, S. et al. Identification of midbrain floor plate radial glia-like cells as dopaminergic progenitors. Glia 56, 809-820 (2008
115. Ono, Y. et al. Differences in neurogenic potential in floor plate cells along an anteroposterior location: midbrain dopaminergic neurons originate from mesencephalic floor plate cells. Development 134, 3213-3225 (2007
116. Placzek, M. & Briscoe, J. The floor plate: multiple cells, multiple signals. Nat. Rev. Neurosci. 6, 230-240 (2005
117. Arenas, E., Denham, M. & Villaescusa, J. C. How to make a midbrain dopaminergic neuron. Development 142, 1918-1936 (2015
118. Chambers, S. M. et al. Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling. Nat. Biotechnol. 27, 275-280 (2009
119. Tabar, V. & Studer, L. Pluripotent stem cells in regenerative medicine: challenges and recent progress. Nat. Rev. Genet. 15, 82-92 (2014
120. Fasano, C. A., Chambers, S. M., Lee, G., Tomishima, M. J. & Studer, L. Efficient derivation of functional floor plate tissue from human embryonic stem cells. Cell Stem Cell 6, 336-347 (2010
121. Kirkeby, A. et al. Generation of regionally specified neural progenitors and functional neurons from human embryonic stem cells under defined conditions. Cell Rep. 1, 703-714 (2012
122. Kriks, S. et al. Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinsons disease. Nature 480, 547-551 (2011
123. Grealish, S. et al. Human ESC-derived dopamine neurons show similar preclinical efficacy and potency to fetal neurons when grafted in a rat model of Parkinsons disease. Cell Stem Cell 15, 653-665 (2014
124. Grealish, S. et al. Monosynaptic tracing using modified rabies virus reveals early and extensive circuit integration of human embryonic stem cell-derived neurons. Stem Cell Rep. http://dx.doi.org/10.1016/j.stemcr.2015.04.011
125. Steinbeck, J. A. et al. Optogenetics enables functional analysis of human embryonic stem cell-derived grafts in a Parkinsons disease model. Nat. Biotechnol. 33, 204-209 (2015
126. Rath, A. et al. Survival and functional restoration of human fetal ventral mesencephalon following transplantation in a rat model of Parkinsons disease. Cell Transplant. 22, 1281-1293 (2013
127. Alper, J. Geron gets green light for human trial of ES cell-derived product. Nat. Biotechnol. 27, 213-214 (2009
128. Kanemura, H. et al. Tumorigenicity studies of induced pluripotent stem cell (iPSC)-Derived retinal pigment epithelium (RPE) for the treatment of age-related macular degeneration. PLoS ONE 9, e85336 (2014
129. Kordower, J. H., Chu, Y., Hauser, R. A., Freeman, T. B. & Olanow, C. W. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinsons disease. Nat. Med. 14, 504-506 (2008
130. Li, J. Y. et al. Lewy bodies in grafted neurons in subjects with Parkinsons disease suggest host to graft disease propagation. Nat. Med. 14, 501-503 (2008
131. Chu, Y. & Kordower, J. H. Lewy body pathology in fetal grafts. Ann. N. Y. Acad. Sci. 1184, 55-67 (2010
132. Li, J. Y. et al. Characterization of Lewy body pathology in 12-And 16 year old intrastriatal mesencephalic grafts surviving in a patient with Parkinsons disease. Mov. Disord. 25, 1091-1096 (2010
133. Guo, J. L. & Lee, V. M. Cell to cell transmission of pathogenic proteins in neurodegenerative diseases. Nat. Med. 20, 130-138 (2014
134. Hallett, P. J. et al. Long-term health of dopaminergic neuron transplants in Parkinsons disease patients. Cell Rep. 7, 1755-1761 (2014
135. Abbott, A. Fetal-cell revival for Parkinsons. Nature 510, 195-196 (2014
136. GForce-PD [online], http://www.gforce-pd.com/ (2015
137. Hirsch, E. C., Duyckaerts, C., Javoy-Agid, F., Hauw, J. J. & Agid, Y. Does adrenal graft enhance recovery of dopaminergic neurons in Parkinsons disease?. Ann. Neurol. 27, 676-682 (1990
138. Peterson, D. I., Price, M. L. & Small, C. S. Autopsy findings in a patient who had an adrenal to brain transplant for Parkinsons disease. Neurology 39, 235-238 (1989
139. Olanow, C. W. et al. Autologous transplantation of adrenal medulla in Parkinsons disease. 18-month results. Arch. Neurol. 47, 1286-1289 (1990
140. Hallett, P. J. et al. Successful function of autologous iPSC-derived dopamine neurons following transplantation in a non-human primate model of Parkinsons disease. Cell Stem Cell 16, 269-274 (2015
141. Delcroix, G. J. et al. The therapeutic potential of human multipotent mesenchymal stromal cells combined with pharmacologically active microcarriers transplanted in hemi-parkinsonian rats. Biomaterials 32, 1560-1573 (2011
142. Offen, D. et al. Intrastriatal transplantation of mouse bone marrow-derived stem cells improves motor behavior in a mouse model of Parkinsons disease. J. Neural Transm. Suppl. 133-143 (2007
143. Sanchez-Pernaute, R., Studer, L., Bankiewicz, K. S., Major, E. O. & McKay, R. D. In vitro generation and transplantation of precursor-derived human dopamine neurons. J. Neurosci. Res. 65, 284-288 (2001
144. Caiazzo, M. et al. Direct generation of functional dopaminergic neurons from mouse and human fibroblasts. Nature 476, 224-227 (2011
145. Pfisterer, U. et al. Direct conversion of human fibroblasts to dopaminergic neurons. Proc. Natl Acad. Sci. USA 108, 10343-10348 (2011